课题基金 / 基金详情

Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management

Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
路易斯安那州解决糖尿病问题的实验:零美元共付额 (LEAD-ZDC) 改善疾病管理
批准号:
10223877
负责人:
LIZHENG SHI
金额:
$45.74万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-30 至 2025-09-29

项目摘要

项目成果

LIZHENG SHI的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 2型糖尿病(T2 DM)仍然是美国的主要公共卫生问题,特别是在 路易斯安那州,糖尿病并发症和心血管疾病(CVD)的死亡率很高, 糖尿病管理在糖尿病管理中,药物治疗不依从性很普遍,且成本很高 药物治疗的成本相关不依从性(CRN)必须作为社会 健康的决定因素。我们建议路易斯安那州自然实验中心(LNEC),包括 学术/研究机构、付款人、社区非营利组织和社区/患者合作伙伴, 和卫生系统,以改善对糖尿病的护理,减少风险因素和并发症。LNEC将在 通过健康研究行动网络(REACHnet)的基础设施得到加强。LNEC的路易斯安那州 解决糖尿病的实验:零美元共同支付(LEAD-ZDC)项目将审查该政策 ZDC降低选定药物(抗糖尿病药、抗高血压药和 他汀类药物)在完全保险的蓝十字和路易斯安那州蓝盾(BCBSLA)成员与T2 DM。的 假设ZDC计划将改善药物依从性并最终改善健康 结果。总体目标是研究ZDC如何减少CRN、总体药物不依从性、健康 护理利用和糖尿病并发症。这三个具体目标将根据范围进行评估, 有效性、采用、实施和维护(RE-AIM)框架。第一个目标是评估 ZDC计划的健康影响如何改善主要有效性指标:药物依从性 使用ZDC降糖药列表和多个次要有效性指标,如总体药物治疗 依从性,依从风险因素药物(抗高血压药和他汀类药物),糖尿病控制, 并发症、医疗保健利用和患者报告的结局。第二个目标是评估 障碍(如种族/民族和农村/城市的差距)和促进者有关的ZDC计划在路易斯安那州。 第三个目的是从卫生系统和社会两个方面评估ZDC项目的成本效益 使用建模技术的观点。患者和利益相关者的参与将作为 LEAD-ZDC项目的基石,该项目将探讨患者,提供者,卫生系统和 社区层面,告知,参与和授权患者,并与T2 DM患者合作和支持, 取得更好的健康成果。拟议的研究将产生迫切需要的数据, 以及消除健康差距和减少糖尿病相关疾病负担的可持续计划。的 研究结果将有助于(1)患者更好地获得所需药物,以及(2)提供者和支付者 更好地了解如何解决遵守的障碍,以便他们可以更好地与 让患者负担得起药物,改善糖尿病的结果。进一步传播和扩大 这些努力将为美国更多样化的卫生系统和支付者创造巨大回报。
英文摘要
Abstract Type 2 diabetes mellitus (T2DM) remains a major public health concern in the United States, especially in Louisiana where mortality from diabetes complications and cardiovascular disease (CVD) is high due to poor diabetes management. Medication treatment non-adherence is prevalent and costly in diabetes management where Cost-Related Non-adherence (CRN) with medication therapies has to be addressed as part of the social determinants of health. We propose a Louisiana Natural Experiment Center (LNEC) that includes academic/research institutions, payers, community non-profit organizations and community/patient partners, and health systems to improve care for diabetes and reduce risk factors and complications. The LNEC will be enhanced by the infrastructure of Research Action for Health Network (REACHnet). The LNEC's Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) project will examine the policy intervention of lowering out-of-pocket cost by ZDC for select medications (antidiabetics, antihypertensives, and statins) among fully insured Blue Cross and Blue Shield of Louisiana (BCBSLA) members with T2DM. The hypothesis is that the ZDC program will improve medication adherence and ultimately improve health outcomes. The overall goal is to study how ZDC may reduce CRN, overall medication non-adherence, health care utilization, and diabetes complications. The three specific aims will be evaluated according to the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework. The first aim is to evaluate how health impacts of the ZDC program improve the primary effectiveness measure: medication adherence with ZDC list of antidiabetics and multiple secondary effectiveness measures such as overall medication adherence, adherence with medications for risk factors (antihypertensives and statins), diabetes control, complications, health care utilization, and patient-reported outcomes. The second aim is to evaluate the barriers (e.g. racial/ethnic and rural/urban disparities) and facilitators related to the ZDC program in Louisiana. The third aim is to estimate the cost-effectiveness of the ZDC program from health system and social perspectives using modelling techniques. Patient and stakeholder engagement will be implemented as a cornerstone of the LEAD-ZDC project, which will explore the barriers at patient, provider, health system, and community levels, to inform, engage and empower patients, and to partner with and support T2DM patients to achieve better health outcomes. The proposed study will generate urgently needed data on effective, practical, and sustainable programs for eliminating health disparities and reducing diabetes-related disease burden. The study findings will assist (1) patients with better access to needed medications, and (2) providers and payers with improved understanding of how to address barriers to adherence so that they may better work with patients to make medications affordable and improve diabetes outcomes. Further dissemination and scale-up efforts will create large returns for more diverse health systems and payers in the United States.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Impact of Medicaid Postpartum Coverage Extension and Mandated Postpartum Depression Screening on Care for Gestational Diabetes and Pregnancy-Induced Hypertension
  • 批准号:
    10749378
  • 项目类别:
  • 资助金额:
    $65.41万
  • 财政年份:
    2023
  • 负责人:
    LIZHENG SHI
  • 依托单位:
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
  • 批准号:
    10650203
  • 项目类别:
  • 资助金额:
    $45.75万
  • 财政年份:
    2020
  • 负责人:
    LIZHENG SHI
  • 依托单位:
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
  • 批准号:
    10097610
  • 项目类别:
  • 资助金额:
    $44.99万
  • 财政年份:
    2020
  • 负责人:
    LIZHENG SHI
  • 依托单位:
Estimating Costs of Supporting Safety-Net PCMH Transformation in New Orleans
  • 批准号:
    8628492
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2013
  • 负责人:
    LIZHENG SHI
  • 依托单位:
海外基金